Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Marie P. Shieh"'
Publikováno v:
Clinical Medicine Insights: Oncology, Vol 5 (2011)
The treatment of chronic myelogenous leukemia (CML) was revolutionized by the development of imatinib mesylate, a small molecule inhibitor of several protein tyrosine kinases, including the ABL1 protein tyrosine kinase. The current second generation
Externí odkaz:
https://doaj.org/article/89a5d14e8a48413390e81249c3e19d40
Autor:
Sharmila Mallya, Matthew R. Janes, Lian-Sheng Li, Katti Jessen, Michael B. Lilly, Yi Liu, David A. Fruman, Collin Vu, Leonard S. Sender, Michael B. Martin, Jose J. Limon, Christian Rommel, Marie P. Shieh, Pingda Ren
Publikováno v:
Janes, Matthew R.; Vu, Collin; Mallya, Sharmila; Shieh, Marie; Limon, Jose J.; Li, Lian-Sheng; et al.(2012). Efficacy of the investigational mTOR kinase inhibitor MLN0128 / INK128 in models of B-cell acute lymphoblastic leukemia. Leukemia, 27(3), 586-594. UC Irvine: Institute for Clinical and Translational Science. Retrieved from: http://www.escholarship.org/uc/item/6wj4c6f6
The mechanistic target of rapamycin (mTOR) is a serine/threonine kinase whose activity contributes to leukemia proliferation and survival. Compounds targeting the mTOR active site inhibit rapamycin-resistant functions and have enhanced anti-cancer ac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f384753a13fb9a31c1536acf943c9ef
https://europepmc.org/articles/PMC3593948/
https://europepmc.org/articles/PMC3593948/
Autor:
Richie Soong, Ross A. Soo, Marie P. Shieh, Tomoya Kawaguchi, Sai-Hong Ignatius Ou, Tony Mok, Byoung Chul Cho, Marie Loh
Publikováno v:
Future oncology (London, England). 8(4)
It is increasingly recognized that differences in overall survival and toxicity exist between Asian and caucasian patients with small-cell and non-small-cell lung cancer, with a longer survival, higher response rates and greater toxicity to chemother
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4cab240e1e4a035497ef1fb703d1d38
https://pubmed.ncbi.nlm.nih.gov/22515448
https://pubmed.ncbi.nlm.nih.gov/22515448
Publikováno v:
Clinical advances in hematologyoncology : HO. 10(1)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::df8bbcadf7a52e261e2061a13cd2bf6f
https://pubmed.ncbi.nlm.nih.gov/22398810
https://pubmed.ncbi.nlm.nih.gov/22398810
Publikováno v:
Clinical Medicine Insights. Oncology
Clinical Medicine Insights: Oncology, Vol 5 (2011)
Clinical Medicine Insights: Oncology, Vol 5 (2011)
The treatment of chronic myelogenous leukemia (CML) was revolutionized by the development of imatinib mesylate, a small molecule inhibitor of several protein tyrosine kinases, including the ABL1 protein tyrosine kinase. The current second generation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1739b9ed7819a0eb8c51d55e4389e4f7
https://pubmed.ncbi.nlm.nih.gov/21792346
https://pubmed.ncbi.nlm.nih.gov/21792346
Autor:
Leonard S. Sender, Michael B. Lilly, Collin Vu, Yi Liu, Matthew R. Janes, David A. Fruman, Christian Rommel, Pingda Ren, Sharmila Mallya, Michael Martin, Marie P. Shieh
Publikováno v:
Blood. 118:2585-2585
Abstract 2585 Pre-B Acute Lymphoblastic Leukemia (B-ALL) remains a significant cause of morbidity and mortality in both adults and children. Targeting signaling pathways that sustain B-ALL cell survival is a promising strategy to improve treatment ou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::118f113e059983b7170bc5f30b42c196
https://doi.org/10.1182/blood.v118.21.2585.2585
https://doi.org/10.1182/blood.v118.21.2585.2585